DelveInsight’s “Candidemia Pipeline Insight 2023” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Candidemia pipeline landscape. It covers the Candidemia pipeline drug profiles, including Candidemia clinical trials and nonclinical stage products. It also covers the Candidemia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Recent Developmental Activities in the Candidemia Treatment Landscape
Discover the recent breakthroughs happening in the Candidemia Pipeline landscape @ Candidemia Pipeline Outlook
Key Takeaways from the Candidemia Pipeline Report
Candidemia Emerging Drugs Profile
Cidara is developing a novel once-weekly echinocandin, rezafungin, for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism, enhancing its efficacy and safety potential for patients. For the treatment of candidemia and invasive candidiasis, rezafungin has designations for Qualified Infectious Disease Product, or QIDP, Fast Track, and Orphan Drug. QIDP and Orphan Drug designations together provide a total of 12 years of marketing exclusivity in the United States from the time of FDA approval. Originally, this compound was owned by Seachaid Pharmaceuticals. Rezafungin acetate is now licensed by Mundipharma International and under the development of Cidara Therapeutics. The drug is currently being evaluated in Phase III stage of development for the treatment of patients with Candidemia.
Get More Information on the Candidemia Drugs and Companies of Report @ Candidemia Ongoing Clinical Trials Analysis
Scope of the Candidemia Pipeline Report
Find out more about the list of FDA-approved drugs for Candidemia @ Candidemia Treatment Landscape
Table of Content
Got Queries? Find out the related information on Candidemia Preclinical and Discovery Stage Products @ Candidemia Drugs, Unmet Needs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/